Akari Therapeutics PLC
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $22.26 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Akari Therapeutics PLC had its IPO on 2015-09-21 under the ticker symbol AKTX.
The company operates in the Healthcare sector and Biotechnology industry. Akari Therapeutics PLC has a staff strength of 9 employees.
Shares of Akari Therapeutics PLC opened at $3.67 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.6 - $3.83, and closed at $3.68.
This is a +4.93% increase from the previous day's closing price.
A total volume of 14,070 shares were traded at the close of the day’s session.
In the last one week, shares of Akari Therapeutics PLC have increased by +10.18%.
Akari Therapeutics PLC's Key Ratios
Akari Therapeutics PLC has a market cap of $22.26 million, indicating a price to book ratio of 3.4316 and a price to sales ratio of 0.
In the last 12-months Akari Therapeutics PLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $-18391610. The EBITDA ratio measures Akari Therapeutics PLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Akari Therapeutics PLC’s operating margin was 0% while its return on assets stood at -141.94% with a return of equity of -365.06%.
In Q2, Akari Therapeutics PLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Akari Therapeutics PLC’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Akari Therapeutics PLC’s profitability.
Akari Therapeutics PLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.1103. Its price to sales ratio in the trailing 12-months stood at 0.
Akari Therapeutics PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.37 million
- Total Liabilities
- $3.05 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Akari Therapeutics PLC ended 2023 with $11.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.37 million while shareholder equity stood at $8.33 million.
Akari Therapeutics PLC ended 2023 with $0 in deferred long-term liabilities, $3.05 million in other current liabilities, 593492.00 in common stock, $-210561421.00 in retained earnings and $0 in goodwill. Its cash balance stood at $8.15 million and cash and short-term investments were $8.15 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Akari Therapeutics PLC’s total current assets stands at $11.35 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.63 million and inventory worth $0.
In 2023, Akari Therapeutics PLC's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Akari Therapeutics PLC paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Akari Therapeutics PLC stock is currently trading at $3.68 per share. It touched a 52-week high of $1.61 and a 52-week low of $1.61. Analysts tracking the stock have a 12-month average target price of $2.75.
Its 50-day moving average was $3.89 and 200-day moving average was $5.85 The short ratio stood at 0.67 indicating a short percent outstanding of 0%.
Around 755.3% of the company’s stock are held by insiders while 1211.7% are held by institutions.
Frequently Asked Questions About Akari Therapeutics PLC
Similar Industry Stocks (Biotechnology)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.